Advanced search
Publication Cover
Acta Oncologica Volume 59, 2020 - Issue 3
Journal homepage
1,322
Views
5
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: MEDICAL ONCOLOGY

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Kalle E. MattilaFican West Cancer Centre, Department of Oncology and Radiotherapy, University of Turku, Turku, Finland; ;Turku University Hospital, Turku, Finland; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-9688-9187View further author information
ORCID Icon,
Pia VihinenFican West Cancer Centre, Department of Oncology and Radiotherapy, University of Turku, Turku, Finland; ;Turku University Hospital, Turku, Finland; View further author information
,
Susan RamadanFican West Cancer Centre, Department of Oncology and Radiotherapy, University of Turku, Turku, Finland; ;Turku University Hospital, Turku, Finland; View further author information
,
Tanja SkyttäDepartment of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland; ;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; View further author information
,
Leena TiainenDepartment of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland; ;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; View further author information
,
Meri-Sisko VuoristoDepartment of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland; ;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; View further author information
,
Kristiina Tyynelä-KorhonenCenter of Oncology, Kuopio University Hospital, Kuopio, Finland; View further author information
,
Jussi KoivunenDepartment of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland; View further author information
,
Laura KohtamäkiHYKS Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, FinlandView further author information
,
Siru MäkeläHYKS Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, FinlandView further author information
&
Micaela HernbergHYKS Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, FinlandORCID Iconhttp://orcid.org/0000-0002-0139-4596View further author information
ORCID Icon show all
Pages 310-314 | Received 31 May 2019, Accepted 17 Sep 2019, Published online: 28 Sep 2019

Figures & data

Table 1. Patient characteristics.

Figure 1. Trial flow chart.

Figure 1. Trial flow chart.

Figure 2. Kaplan–Meier survival curves. (A) OS in cohort 1 and 2; (B) PFS in cohort 1 and 2; (C) OS in patients with normal baseline LDH and elevated baseline LDH; (D) OS in patients with and without baseline brain metastases.

Figure 2. Kaplan–Meier survival curves. (A) OS in cohort 1 and 2; (B) PFS in cohort 1 and 2; (C) OS in patients with normal baseline LDH and elevated baseline LDH; (D) OS in patients with and without baseline brain metastases.
Supplemental material

Supplemental Material

Download MS Word (28.5 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma
Source: Taylor & Francis
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma
Source: Taylor & Francis

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.